Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial

AIM: To evaluate the activity and safety of the PD-1 antibody pembrolizumab in adult patients with advanced osteosarcoma. MATERIAL AND METHODS: The study was a single-arm, open-label, phase 2 trial in patients with unresectable, relapsed osteosarcoma. The primary endpoint was clinical benefit rate (...

Descripción completa

Detalles Bibliográficos
Autores principales: Boye, Kjetil, Longhi, Alessandra, Guren, Tormod, Lorenz, Susanne, Næss, Stine, Pierini, Michela, Taksdal, Ingeborg, Lobmaier, Ingvild, Cesari, Marilena, Paioli, Anna, Løndalen, Ayca M., Setola, Elisabetta, Hompland, Ivar, Meza-Zepeda, Leonardo A., Sundby Hall, Kirsten, Palmerini, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360887/
https://www.ncbi.nlm.nih.gov/pubmed/33580363
http://dx.doi.org/10.1007/s00262-021-02876-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360887/
https://www.ncbi.nlm.nih.gov/pubmed/33580363
http://dx.doi.org/10.1007/s00262-021-02876-w

Ejemplares similares